<DOC>
	<DOCNO>NCT00755079</DOCNO>
	<brief_summary>The primary purpose study determine effect administration oral beta-2 adrenergic agonist , albuterol , respiratory muscle strength individual cervical ( neck ) high thoracic ( upper back ) spinal cord injury compare finding obtain demographically match group receive placebo . Participation study involve 12 week pharmacological intervention participant randomize receive either oral albuterol 4mg twice daily placebo . All investigator study participant blind randomization research pharmacy . Participation study require study subject come lab total 2 visit ( baseline week 12 ) , series test perform assess respiratory muscle strength pulmonary function .</brief_summary>
	<brief_title>Use Oral Beta-2 Agonist Persons With Spinal Cord Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Adrenergic Agents</mesh_term>
	<mesh_term>Adrenergic Agonists</mesh_term>
	<criteria>Chronic Spinal Cord Injury ( &gt; 1 year postinjury ) All American Spinal Injury Association ( ASIA ) classification High Paraplegia ( level injury T1T6 ) Tetraplegia ( level injury C2C8 , nonventilator dependent ) history asthma uncontrolled hypertension cardiovascular disease use beta2 adrenergic agonist epilepsy seizure disorder hyperthyroidism chronic corticosteroid use take monoamine oxidase inhibitor Tricyclic antidepressant depression hypersensitivity albuterol ' delete component pregnancy use ergogenic aid supplement anabolic characteristic include , limited : creatine monohydrate anabolic steroid ( e.g. , testosterone ) growth hormone analog and/or derivative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>spinal cord injury</keyword>
	<keyword>beta-2 agonist</keyword>
	<keyword>respiratory muscle strength</keyword>
	<keyword>pulmonary function test</keyword>
</DOC>